SPTSSA: A Potential Drug Target and Biomarker (G171546)

Target Name: SPTSSA

NCBI ID: G171546

SPTSSA

SPTSSA: A Potential Drug Target and Biomarker

Spermidine- Specific Protein Trap (SPTSSA) is a protein that is expressed in various tissues and cells throughout the body. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SPTSSA is a member of the sphingomyelinase family, which is a group of enzymes that are involved in the break down of sphingomyelin, a major component of cell membranes. This family of enzymes has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SPTSSA has been shown to play a key role in the development of cancer. Many studies have shown that high levels of SPTSSA are associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, SPTSSA has been shown to promote the growth and survival of cancer cells, which may contribute to its role in the development of cancer.

SPTSSA has also been identified as a potential biomarker for neurodegenerative diseases. Many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. SPTSSA has been shown to be involved in the development and progression of these diseases, and may be a useful biomarker for these conditions.

SPTSSA has also been shown to be involved in the development and progression of autoimmune disorders. Many autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues and organs. SPTSSA has been shown to be involved in the development and progression of these disorders, and may be a useful biomarker for these conditions.

In conclusion, SPTSSA is a protein that has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand its role in the development and progression of these conditions.

Protein Name: Serine Palmitoyltransferase Small Subunit A

Functions: Stimulates the activity of serine palmitoyltransferase (SPT). The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA (PubMed:19416851). Plays a role in MBOAT7 location to mitochondria-associated membranes (MAMs), may me involved in fatty acid remodeling phosphatidylinositol (PI) (PubMed:23510452)

The "SPTSSA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPTSSA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets